Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
Conditions: Allogeneic Hematopoietic Stem Cell Transplantation Recipient; Blasts 5 Percent or More of Bone Marrow Nucleated Cells; Blasts 5 Percent or More of Peripheral Blood White Cells; CD22 Positive; Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells; Lymphoblasts 20 Percent or More of Peripheral Blood White Cells; Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia Interventions: Biological: Inotuzumab Ozogamicin; Other: Quality-of-Life Assessment; Drug: Vincristine Sulfate Liposome Sponsors: Roswell Park Cancer Institute; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Leukemia | Research | Stem Cell Therapy | Stem Cells | Transplants